Related Experiment Video
Updated: Jun 25, 2026

Use of a Foot-Induced Digitally Controlled Resistance Device for Functional Magnetic Resonance Imaging Evaluation in Patients with Foot Paresis
Published on: July 7, 2023
[Hand-foot syndrome and sorafenib]
1Service de pharmacologie, centre Antoine-Lacassagne, 33 avenue Valombrose, Nice cedex 01, France.
Abstract:
Sorafenib (Nexavar) is a targeted therapy acting as VEGFR and PDGFR tyrosine-kinase inhibitor that has been approved in France in the treatment of metastatic renal cell carcinoma and hepatocarcinoma. Hand-foot syndrome is one of the more frequent toxicity related to sorafenib. This paper up lights the main points concerning this toxicity in the view of specialists working together in the care of these patients: a pharmacologist, a dermatologist and a medical oncologist. The clinic and symptoms of hand-foot syndrome as the biological interpretation, the symptomatic treatment and the impact on the specific treatment of sorafenib are developed.
Related Concept Videos
Diabetic Foot Ulcer
Diabetic Neuropathy
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Diabetic Nephropathy
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome III : Nursing Management